Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
48 (est)
Dicerna Pharmaceuticals was founded in 2007 and is headquartered in Cambridge, US

Key People at Dicerna Pharmaceuticals

Douglas Fambrough

Douglas Fambrough

CEO
Bob D. Brown

Bob D. Brown

CSO

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridge Park Dr

Dicerna Pharmaceuticals Data and Metrics

Dicerna Pharmaceuticals Financial Metrics

Dicerna Pharmaceuticals's revenue was reported to be $295 k in FY, 2016 which is a 60% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

295 k

Revenue growth (FY, 2015 - FY, 2016), %

60%

Net income (FY, 2016)

(59.5 m)

EBIT (FY, 2016)

(59.7 m)

Market capitalization (25-May-2017)

68.6 m

Closing share price (25-May-2017)

3.3

Cash (31-Dec-2016)

20.9 m
Dicerna Pharmaceuticals's current market capitalization is $68.6 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Revenue

184 k295 k

Revenue growth, %

60%

R&D expense

29.5 m44 m41.7 m

General and administrative expense

15.6 m19.2 m18.3 m

Operating expense total

45.1 m63.2 m60 m

EBIT

(45.1 m)(63 m)(59.7 m)

EBIT margin, %

(34254%)(20254%)

Interest expense

(199 k)(199 k)(199 k)

Interest income

63 k188 k235 k

Net Income

(47.9 m)(62.8 m)(59.5 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Cash

26.1 m56.1 m20.9 m

Accounts Receivable

254.7 m

Inventories

1.2 m1.5 m2 m

Current Assets

97.3 m96.1 m47.8 m

PP&E

2.2 m2.7 m2.2 m

Total Assets

103.6 m100 m51.3 m

Accounts Payable

1.2 m2.6 m4.3 m

Current Liabilities

5.2 m9 m10 m

Non-Current Liabilities

106 k106 k

Total Liabilities

5.3 m9.1 m

Additional Paid-in Capital

231.7 m287.3 m297 m

Retained Earnings

(133.4 m)(196.2 m)(255.8 m)

Total Equity

91 m41.2 m

Financial Leverage

1.1 x1.2 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(47.9 m)(62.8 m)(59.5 m)

Depreciation and Amortization

848 k727 k840 k

Accounts Receivable

(15.1 m)

Inventories

(44.3 m)

Accounts Payable

(97 k)1.4 m1.6 m

Cash From Operating Activities

(20.5 m)30 m(48.7 m)

Purchases of PP&E

(2 m)(1.1 m)(449 k)

Cash From Investing Activities

(75.8 m)33 m13 m

Long-term Borrowings

(5 m)

Cash From Financing Activities

90 m45.8 m534 k

Interest Paid

194 k194 k194 k
Y, 2016

Financial Leverage

1.2 x

Dicerna Pharmaceuticals Market Value History

Dicerna Pharmaceuticals Online and Social Media Presence

Dicerna Pharmaceuticals News and Updates

Dicerna Pharmaceuticals Company Life and Culture

You may also be interested in